Black Diamond Therapeutics reported updated Phase 2 results for silevertinib, its experimental treatment for people with newly diagnosed, or frontline, non-small cell lung cancer (NSCLC) with non-classical EGFR mutations. The company also outlined a potential pivotal-trial path after discussions with the FDA and reported that its cash and investments are expected to fund operations into the second half of 2028.
-
Updated clinical data: At an October 7, 2026 cutoff, 43 patients in the U.S. and Canada had received silevertinib at 200 mg once daily. Median follow-up was 15.9 months. The trial covered a broad range of EGFR non-classical mutations.
-
Activity in the brain: Black Diamond highlighted an 86% response rate in the central nervous system among patients with untreated brain metastases. It also said median progression-free survival in this group was twice that seen with currently available EGFR inhibitors. The announcement did not provide the underlying median survival figures.
-
No new brain metastases reported: A clinical investigator said no frontline patient treated with silevertinib had developed new brain metastases during the reported experience. The company characterized delaying progression in the brain as an important part of the treatment’s potential benefit.
-
FDA feedback and next steps: Following an end-of-Phase 2 meeting, the FDA’s feedback supported Black Diamond’s plan to develop silevertinib as a pivotal treatment for the broader population of frontline NSCLC patients with EGFR non-classical mutations. The company said the program may support accelerated approval based on the central nervous system response rate, as well as a path toward full approval.
-
Potential patient population: Black Diamond estimates that EGFR non-classical mutations account for about 25% of frontline EGFR-mutant NSCLC patients.
-
Financial runway: The company had $102 million in cash, cash equivalents and investments as of September 30, 2026, which it expects will fund operations into the second half of 2028.
What it means: Silevertinib remains an investigational drug, and the FDA feedback and Phase 2 findings do not amount to approval. The update establishes the company’s intended pivotal-development path and emphasizes brain activity as a central feature of the program.